{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:24:47Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 18.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09524-cdf7-7fe1-9d69-4840c12cb752\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: ifenprodil\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 75.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09524-ce07-7a62-b7f6-b5ee8d462b3f\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: ifenprodil\nRegistry id: vr.tr.ifenprodil\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:51:39+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q5991156", "registryId": "vr.tr.ifenprodil", "name": "ifenprodil", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q5991156/", "model": { "registry_id": "vr.tr.ifenprodil", "name": "ifenprodil", "purpose": "Enable an agent to recognise ifenprodil, evaluate the identity and condition of a supplied material, and determine whether its documented properties support a proposed use.", "definition": "Ifenprodil is a synthetic small-molecule vasodilator and noncompetitive antagonist of GluN2B-containing NMDA receptors, used pharmacologically and as a research tool.", "scope_statement": "This model owns the substance identity vr.tr.ifenprodil in PHY / PHY.MAT, including stereochemical specification, relationships to salt forms, material quality, condition-dependent properties and evidence connecting a characterised material to biological activity.", "in_scope": [ "Ifenprodil molecular identity and externally verified identifiers", "Stereochemical composition and relationships between free base and supplied salts", "Batch purity, impurities, analytical identity and provenance", "Physical state, solubility, stability and concentration basis", "Assay-specific biological activity and substance-level handling constraints" ], "out_of_scope": [ "Finished medicines, packaging and excipient formulations", "Patient-specific prescribing, dosing and treatment decisions", "Manufacturing processes and synthesis routes", "NMDA receptors and other biological targets as independently modelled entities", "Clinical trials, diseases and therapeutic efficacy assessments" ], "distinguishing_features": [ "Match molecular connectivity to 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol rather than accepting a shared pharmacological label as identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil)", "Cross-check the parent record against formula C21H27NO2, CAS 23210-56-2 and PubChem CID 3689; a formula match alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil)", "Require explicit stereochemical evidence before treating a stereospecified material as equivalent to the parent record, whose displayed InChIKey does not specify stereochemistry. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil)", "Distinguish parent ifenprodil from ifenprodil tartrate by counterion and stoichiometry; PubChem maintains a separate tartrate record. [PubChem: Ifenprodil Tartrate](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil-Tartrate)", "Do not identify a material solely through an NMDA-related response: experimental work also reports presynaptic P/Q-type calcium-channel effects. [Primary study](https://pubmed.ncbi.nlm.nih.gov/22205650/)" ], "characteristics": [ { "name": "Parent chemical identity", "kind": "category", "unit_or_values": "Verified structure, formula, CAS, PubChem CID and EC identifier, each with source and chemical-form scope", "why_it_matters": "Prevents conflation of ifenprodil with related compounds or salt records." }, { "name": "Stereochemical specification", "kind": "category", "unit_or_values": "Assigned configurations, specified mixture, or unresolved; include supporting method", "why_it_matters": "An unspecified name does not establish the stereochemical composition of a batch." }, { "name": "Salt and solvation relationship", "kind": "relation", "unit_or_values": "Parent moiety, counterion, molar ratio, hydrate or solvate status, and supporting evidence", "why_it_matters": "Determines the appropriate molecular mass and free-base-equivalent conversion." }, { "name": "Content and purity", "kind": "measurement", "unit_or_values": "Mass fraction or % w/w for content; chromatographic area % recorded separately, with method and reporting basis", "why_it_matters": "A chromatographic purity claim is not necessarily the fraction of weighed material that is ifenprodil." }, { "name": "Stereoisomer composition", "kind": "measurement", "unit_or_values": "Isomer fractions in %, or validated enantiomeric and diastereomeric ratios", "why_it_matters": "Supports meaningful comparison between reference materials and experimental lots." }, { "name": "Physical and solution state", "kind": "state", "unit_or_values": "Solid form or solution; solvent, pH, temperature, precipitation and water content where relevant", "why_it_matters": "Conditions determine whether a prepared material remains suitable for measurement or use." }, { "name": "Condition-dependent physical constants", "kind": "measurement", "unit_or_values": "Solubility in mg/mL or mol/L; thermal transitions in °C; pressure for boiling data; measured or predicted status", "why_it_matters": "Values must apply to the actual chemical form and conditions." }, { "name": "Ifenprodil concentration", "kind": "measurement", "unit_or_values": "mol/L or mg/mL, explicitly reported as supplied compound or parent-if enprodil equivalent", "why_it_matters": "Prevents salt mass, impurity and dilution differences from becoming hidden exposure errors." }, { "name": "Biological activity evidence", "kind": "relation", "unit_or_values": "Material-to-assay link with target composition, species, endpoint, concentration range and source", "why_it_matters": "Keeps activity claims tied to the experiment that supports them." }, { "name": "Handling and regulatory status", "kind": "category", "unit_or_values": "Form-specific hazard classification, applicable exposure limits or unknown status, jurisdiction, intended use and verification date", "why_it_matters": "Supports handling and use decisions without inferring permission from a substance name." } ], "affordances": [ "Reconcile a supplier label and certificate with the ifenprodil parent identity and the actual supplied chemical form.", "Calculate parent-equivalent quantities when salt stoichiometry, solvation and content are established.", "Compare batches using chemical identity, stereochemical composition and analytical quality.", "Assess whether a stock solution has a supported concentration and remains within documented stability conditions.", "Evaluate whether an activity claim applies to the material and assay under consideration.", "Flag material for additional analysis or restricted use when identity, condition or applicable handling evidence is missing." ], "agent_conduct": { "may": [ "Describe ifenprodil, its receptor actions and its uses from official drug information and research sources.", "Report the research grade and handling information of a sample from its safety data sheet.", "Track stock in a laboratory or pharmacy the agent is authorized to manage." ], "must_not": [ "Recommend, dose or adjust ifenprodil for a particular person.", "Promote it for unapproved uses, such as mood or cognitive effects, without clinical evidence.", "Help anyone obtain it without a prescription where one is required.", "Present animal or cell research as proof of benefit in people." ], "requires_human": [ "Any prescribing or clinical trial decision involving the drug." ] }, "ethics": { "considerations": [ "Drugs acting on brain receptors can have serious side effects, so claims must be careful.", "Research tools can be misused as unregulated supplements." ], "affected_parties": [ "Patients", "Research participants", "Laboratory workers" ] }, "owners": { "steward": "The prescribing clinician or the laboratory that holds it; medicines regulators authorize medical use.", "master_systems": [ "National medicines registers" ] }, "failure_modes_and_hazards": [ "Can lower blood pressure and cause dizziness.", "Interactions with other drugs acting on the brain or circulation are possible." ], "what_it_is_for": [ "Ifenprodil is encountered in pharmacological research, particularly studies involving GluN2B-containing NMDA receptors.", "It also appears in pharmaceutical contexts associated with its vasodilator activity, where the chemical form and material specification affect suitability." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology assigns ifenprodil code C04AX28 within other peripheral vasodilators." ], "visual_identification": [ "A container label naming ifenprodil distinguishes its declared contents from other receptor antagonists, although the label does not prove chemical identity.", "The label or accompanying material record should distinguish the free base from a named salt because these are different supplied forms.", "A white or off-white powder appearance is compatible with supplied ifenprodil materials but cannot distinguish them from many unrelated chemicals." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q5991156: ifenprodil", "url": "https://www.wikidata.org/wiki/Q5991156", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Ifenprodil", "url": "https://en.wikipedia.org/wiki/Ifenprodil", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "ifenprodil-identity", "name": "Ifenprodil identity", "description": "Establishes which chemical entity a record or material represents.", "rationale": "The registry name alone does not resolve chemical form or stereochemical specificity.", "layers": [ { "id": "parent-structure", "name": "Parent structure", "description": "Connects the registry entry to verified molecular connectivity and identifiers.", "findings": [ { "id": "identity-concordance", "name": "Identity concordance", "description": "Require agreement between structure and identifiers before accepting an ifenprodil identity.", "questions": [ { "text": "Does the supplied structure match the parent ifenprodil connectivity associated with PubChem CID 3689?", "kind": "definition", "id": "identity-concordance-q01" }, { "text": "Which inspected source establishes each identifier, and does it identify the parent or a particular salt or stereoisomer?", "kind": "provenance", "id": "identity-concordance-q02" } ] } ] }, { "id": "stereochemical-boundary", "name": "Stereochemical boundary", "description": "Separates the parent name from claims about the stereochemistry of actual material.", "findings": [ { "id": "isomer-specification", "name": "Isomer specification", "description": "Record specified configurations and mixture composition without inferring them from an unspecific identifier.", "questions": [ { "text": "What configurations or stereoisomer mixture does this ifenprodil material claim to contain?", "kind": "definition", "id": "isomer-specification-q01" }, { "text": "What analytical evidence establishes its enantiomeric and diastereomeric composition?", "kind": "measurement", "id": "isomer-specification-q02" } ] } ] } ] }, { "id": "ifenprodil-material-basis", "name": "Ifenprodil material basis", "description": "Describes how the parent substance is represented in a supplied solid or solution.", "rationale": "Mass and concentration comparisons require explicit salt, solvation and content information.", "layers": [ { "id": "salt-stoichiometry", "name": "Salt stoichiometry", "description": "Establishes the relationship between ifenprodil and any counterion or bound solvent.", "findings": [ { "id": "supplied-form", "name": "Supplied form", "description": "Treat a salt designation as a relationship requiring a verified formula and ratio.", "questions": [ { "text": "Is the material free-base ifenprodil or a salt, and what counterion-to-ifenprodil ratio is established?", "kind": "definition", "id": "supplied-form-q01" }, { "text": "Does its certificate identify water or solvent contributions that change the mass basis?", "kind": "provenance", "id": "supplied-form-q02" } ] } ] }, { "id": "parent-equivalent-accounting", "name": "Parent-equivalent accounting", "description": "Makes conversions from weighed material to ifenprodil amount traceable.", "findings": [ { "id": "concentration-basis", "name": "Concentration basis", "description": "Require the reported concentration to identify the chemical entity and correction factors used.", "questions": [ { "text": "Is the reported concentration based on salt formula units, total supplied mass or moles of ifenprodil parent?", "kind": "measurement", "id": "concentration-basis-q01" }, { "text": "Are stoichiometry, molecular mass, water content and assay content sufficiently established to calculate parent-equivalent concentration?", "kind": "action", "id": "concentration-basis-q02" } ] } ] } ] }, { "id": "ifenprodil-quality-and-condition", "name": "Ifenprodil quality and condition", "description": "Evaluates analytical quality and the state of an ifenprodil batch or preparation.", "rationale": "A correctly named material can still have uncertain content, unsuitable impurities or an unreliable solution concentration.", "layers": [ { "id": "batch-characterisation", "name": "Batch characterisation", "description": "Connects identity and quality claims to the actual lot.", "findings": [ { "id": "analytical-acceptance", "name": "Analytical acceptance", "description": "Keep structural confirmation, quantitative content and impurity evidence distinct.", "questions": [ { "text": "Which lot-specific analytical results confirm ifenprodil identity and distinguish relevant isomeric or chemical impurities?", "kind": "provenance", "id": "analytical-acceptance-q01" }, { "text": "What are the measured content, chromatographic purity and residual solvent or water levels, with methods and reporting bases?", "kind": "measurement", "id": "analytical-acceptance-q02" } ] } ] }, { "id": "preparation-state", "name": "Preparation state", "description": "Tracks the conditions under which solid material and stock solutions remain characterised.", "findings": [ { "id": "solubility-and-stability", "name": "Solubility and stability", "description": "Attach physical-property and stability claims to the supplied form and preparation conditions.", "questions": [ { "text": "What measured solubility and thermal data apply to this ifenprodil form, with solvent, pH, temperature and method specified?", "kind": "measurement", "id": "solubility-and-stability-q01" }, { "text": "Do storage history, solution age, precipitation or analytical changes require remeasurement before using the stated concentration?", "kind": "action", "id": "solubility-and-stability-q02" } ] } ] } ] }, { "id": "ifenprodil-activity-interpretation", "name": "Ifenprodil activity interpretation", "description": "Links characterised ifenprodil material to evidence for receptor and cellular effects.", "rationale": "An activity label cannot establish universal selectivity or explain every response observed after exposure.", "layers": [ { "id": "nmda-assay-context", "name": "NMDA assay context", "description": "Structures the evidence needed to interpret GluN2B-related activity claims.", "findings": [ { "id": "subunit-dependent-evidence", "name": "Subunit-dependent evidence", "description": "Require explicit receptor composition and assay conditions when evaluating claimed inhibition.", "questions": [ { "text": "Which experiment establishes the claimed ifenprodil effect, and what species and GluN1/GluN2 subunit composition were tested?", "kind": "provenance", "id": "subunit-dependent-evidence-q01" }, { "text": "What endpoint, potency, concentration basis, pH and exposure conditions were measured?", "kind": "measurement", "id": "subunit-dependent-evidence-q02" } ] } ] }, { "id": "alternative-effect-attribution", "name": "Alternative effect attribution", "description": "Tests whether an observed response supports the proposed target attribution.", "findings": [ { "id": "selectivity-limits", "name": "Selectivity limits", "description": "Record alternative pharmacological explanations and the controls needed to distinguish them.", "questions": [ { "text": "What evidence addresses non-NMDA effects, including the reported P/Q-type calcium-channel effect, at the tested concentration?", "kind": "boundary", "id": "selectivity-limits-q01" }, { "text": "Which orthogonal controls are needed before attributing this preparation's observed effect to GluN2B-containing receptors?", "kind": "action", "id": "selectivity-limits-q02" } ] } ] } ] }, { "id": "ifenprodil-handling-and-use", "name": "Ifenprodil handling and use", "description": "Connects material-specific hazard evidence and applicable status to proposed operations.", "rationale": "Handling requirements and permitted uses must be established for the actual form, location and purpose.", "layers": [ { "id": "form-specific-hazards", "name": "Form-specific hazards", "description": "Associates handling decisions with evidence for the supplied chemical form and preparation.", "findings": [ { "id": "hazard-evidence", "name": "Hazard evidence", "description": "Keep verified classifications and exposure limits separate from absent or unresolved information.", "questions": [ { "text": "Which current safety data sheet or authoritative assessment covers this ifenprodil form and concentration?", "kind": "provenance", "id": "hazard-evidence-q01" }, { "text": "What hazard classification, exposure limits and handling or disposal requirements does that evidence establish?", "kind": "action", "id": "hazard-evidence-q02" } ] } ] }, { "id": "use-status-boundary", "name": "Use status boundary", "description": "Separates substance identification from permission to use a particular material for a particular purpose.", "findings": [ { "id": "documented-use-eligibility", "name": "Documented use eligibility", "description": "Evaluate intended use using dated jurisdictional evidence and the supplied grade.", "questions": [ { "text": "What jurisdiction, intended use and material grade apply to the proposed operation involving ifenprodil?", "kind": "boundary", "id": "documented-use-eligibility-q01" }, { "text": "Which dated authoritative record establishes applicable restrictions or permissions, and does it concern the substance or a specific medicinal product?", "kind": "provenance", "id": "documented-use-eligibility-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall only; no sources were consulted.", "Verify CAS and other registry identifiers against the exact salt and stereochemical identity.", "Check current regional authorization, hazard classifications and form-specific physical properties before adding them." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Ifenprodil free base", "Ifenprodil tartrate" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "ifenprodil", "note": "Names the active substance; salt form should be specified separately." }, { "scheme": "Molecular formula", "value_or_pattern": "C21H27NO2", "note": "Applies to the neutral free base, not the tartrate salt." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Research on GluN2B-containing NMDA receptors and their contribution to neuronal signalling.", "Experimental investigation of excitotoxicity and neuroprotection.", "Historical medicinal use as a vasodilator in some countries." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the free base", "typical_range": "325.45", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Vasodilatory and alpha-adrenergic antagonist activity can cause hypotension.", "Activity at targets other than NMDA receptors can confound experiments that treat it as exclusively GluN2B-selective.", "Confusing free-base and tartrate molecular masses can produce concentration or dose calculation errors." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Medicinal authorization, indications and availability vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Ifenprodil tartrate", "difference": "A salt form containing ifenprodil and tartrate; its composition and formula mass differ from those of the free base." }, { "name": "Eliprodil", "difference": "A chemically distinct, related NMDA receptor antagonist, not a synonym or salt of ifenprodil." }, { "name": "Memantine", "difference": "An NMDA receptor channel blocker with a different mechanism and selectivity profile from ifenprodil's GluN2B-preferring allosteric antagonism." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of ifenprodil this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the registry intend a particular stereoisomer mixture, or should vr.tr.ifenprodil retain a stereochemically unspecified parent identity?", "Which salt stoichiometries and hydrate or solvate forms occur in the materials to be represented, and how should their identifiers link to the parent?", "Which measured solubility, thermal and storage-stability values are sufficiently reliable for each relevant chemical form?", "What concentration-dependent evidence establishes GluN2B-related activity and alternative target effects for the intended experimental systems?", "Which current form-specific hazard classifications, exposure limits and jurisdictional use restrictions can be established from authoritative records?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }